The efficacy of pregabalin for treating pain associated with diabetic peripheral neuropathy in subjects with type 1 or type 2 diabetes mellitus

Primary tabs

SCIENCE
The efficacy of pregabalin for treating pain associated with diabetic peripheral neuropathy in subjects with type 1 or type 2 diabetes mellitus
Key Take-Away: 

Diabetic peripheral neuropathy is a devastating issue that involves nerve damage due to high blood glucose levels. Pregabalin is an FDA approved the drug to counter DPN associated pain but its role as per diabetic types. The study helps to elucidate the efficacy of Pregabalin among type one and two diabetic patients.

Introduction
The study aimed to compare the Pregabalin safety and efficacy in concern to painful diabetic peripheral neuropathy (pDPN) management among people with type1/type 2 diabetes mellitus (T2DM).

 

Methods
Ten randomised clinical trials were analysed to collect the pooled data regarding change sleep disturbance and pain scores from baseline to 12 weeks and last observation carried forward (LOCF) using mixed model repeated measures (MMRM). The Adverse events (AEs) were also noticed.

 

Results
The placebo (T1DM/T2DM; 92/868) and Pregabalin-treated (T1DM/T2DM; 1632/156) were compared the baseline demographic features. T1DM group patients were ∼10 years younger than T2DM patients. The mean ± SD baseline sleep and pain scores for Pregabalin and placebo noticed were (T1DM: 5.2 ± 2.4 and 5.2 ± 2.7; T2DM: 5.3 ± 2.5 and 5.1 ± 2.5) and (T1DM: 6.2 ± 1.4 and 6.5 ± 1.6; T2DM: 6.5 ± 1.5 and 6.4 ± 1.5), respectively were comparable. Mean CFB treatment differences (pregabalin minus placebo) measured by MMRM were considerably diverse for sleep and pain with each diabetes types (all weeks p < .05). With LOCF, Podds ratios (ORs) of achieving 30% pain reduction of Pregabalin’s were comparable with T1DM (2.01) and T2DM (1.91). ORs of 30% improvement in sleep quality of Pregabalin was 1.81 with T1DM and 2.01 with T2DM. AEs were compatible with the safety profile of Pregabalin.

 

Conclusions
Pregabalin improved pain and sleep quality remarkably, without a clinically meaningful variation between diabetes types.

Source:

Curr Med Res Opin

Link to the source:

https://www.ncbi.nlm.nih.gov/pubmed/30084288

Original title of article:

The efficacy of pregabalin for treating pain associated with diabetic peripheral neuropathy in subjects with type 1 or type 2 diabetes mellitus.

Authors:

B. Parsons et al.

Therapeutic, Pregabalin, Diabetic Neuropathy, Nerves, Anticonvulsant, Efficacy, ORs
Log in or register to post comments